Remeglurant

Remeglurant (INNTooltip International Nonproprietary Name; developmental code name MRZ-8456) is a drug which acts as a selective antagonist of the mGlu₅ receptor.^[1][2][3] It is under development by Merz Pharmaceuticals for the treatment of drug-induced dyskinesia but no development has been reported since at least 2016.^[3]

Remeglurant

Clinical data
Other names	MRZ-8456
ATC code	None
Identifiers
IUPAC name (6-Bromopyrazolo[1,5-a]pyrimidin-2-yl)[(1R)-1-methyl-3,4-dihydro-2(1H)-isoquinolinyl]methanone
CAS Number	1309783-00-3
PubChem CID	24810684
ChemSpider	32701693
UNII	Y7H8880HMD
CompTox Dashboard (EPA)	DTXSID501032318
Chemical and physical data
Formula	C17H15BrN4O
Molar mass	371.238 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@@H]1c2ccccc2CCN1C(=O)c3cc4ncc(cn4n3)Br
InChI InChI=1S/C17H15BrN4O/c1-11-14-5-3-2-4-12(14)6-7-21(11)17(23)15-8-16-19-9-13(18)10-22(16)20-15/h2-5,8-11H,6-7H2,1H3/t11-/m1/s1 Key:TUYZYSNXXSTKQX-LLVKDONJSA-N

See also

• Basimglurant
• Dipraglurant
• Fenobam
• Mavoglurant
• Raseglurant